Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 21, 2023
Product Development

Equitable access to new modalities: from innovation to reimbursement

Perspectives from innovators and policy professionals on what it takes to get next-generation technologies to diverse populations
BioCentury | Feb 2, 2018
Finance

Building momentum

Why investors flocked to cell therapy company Avrobio’s $60M series B round
BioCentury | Feb 1, 2018
Financial News

Cell therapy play Avrobio raises $60M

BioCentury | Dec 1, 2017
Company News

Avrobio acquires cystinosis program from GenStem

BioCentury | Nov 30, 2017
Targets & Mechanisms

All-purpose HSCs

UCSD spins out GenStem to develop HSC therapies for genetic diseases
BioCentury | Nov 4, 2013
Company News

Raptor, DaVita HealthCare Partners deal

Items per page:
1 - 6 of 6
Help Center
Username
Request a Demo
Request Training
Ask a Question